Walled Lake Planning & Wealth Management LLC Purchases 1,165 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Walled Lake Planning & Wealth Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 85,435 shares of the biopharmaceutical company’s stock after acquiring an additional 1,165 shares during the quarter. Gilead Sciences accounts for about 2.9% of Walled Lake Planning & Wealth Management LLC’s investment portfolio, making the stock its 8th biggest position. Walled Lake Planning & Wealth Management LLC’s holdings in Gilead Sciences were worth $7,892,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Norges Bank acquired a new position in Gilead Sciences in the fourth quarter worth about $1,789,254,000. Wellington Management Group LLP lifted its holdings in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $207,340,000. Finally, Point72 Asset Management L.P. raised its position in shares of Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.6 %

NASDAQ:GILD opened at $111.79 on Friday. The company has a market capitalization of $139.22 billion, a P/E ratio of 302.14, a P/E/G ratio of 0.71 and a beta of 0.21. The stock’s 50 day moving average price is $105.48 and its 200 day moving average price is $94.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.83%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.